한글목차

세계의 혈장 유도체 시장은 2025년 529억 6,000만 달러로 추정되고, 2032년까지 986억 9,000만 달러에 이를 것으로 예측되고, 2025년부터 2032년까지 CAGR 9.3%를 보일 것으로 예측됩니다.

혈장은 혈액의 액체 부분입니다. 혈액의 약 55%는 혈장이며, 나머지 45%는 혈장 중에 부유하는 적혈구, 백혈구, 혈소판입니다.

시장 역학

유전성 질환 부담 증가, 노인 증가, 혈장 유도체에 대한 높은 수요, 다양한 치료 부문에서 면역글로불린 사용 증가, 혈장 수집 센터 증가는 예측 기간 동안 세계 혈장 유도체 시장의 성장을 증가시킬 것으로 예상되는 주요 요인입니다.

예를 들어 2022년 3월 Sanofi SA와 IGM Biosciences, Inc.는 3개의 종양학과 면역학 및 염증학 표적에 대한 면역글로불린(IgM) 항체 효능제의 창제, 개발, 제조, 상품화로 제휴했습니다. 기존 IgG 항체의 표적 결합 부위가 2개였던 것에 대해, IgM 항체는 10개의 결합 부위를 가져, 다가성을 겸비한 새로운 치료가 됩니다.

본 조사의 주요 특징

• 본 보고서에서는 세계의 혈장 유도체 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간 2025-2032년 시장 규모와 복합 연간 성장률(CAGR%)을 제공합니다.
• 또, 다양한 부문에 걸친 잠재적인 수익 기회를 밝혀, 이 시장의 매력적인 투자 제안 매트릭스에 대해서 해설했습니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시나 승인, 시장 동향, 지역에 의한 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
• 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 성과, 전략 등의 다음 파라미터를 바탕으로 세계 혈장 유도체 시장의 주요 기업 프로파일을 제공합니다.
• 본 보고서로부터 통찰에 의해 마케팅 담당자나 기업의 경영진은 장래의 제품 발매, 유형, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시할 수 있습니다.
• 혈장 유도체 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통 업체, 신규 참가자, 재무 분석가 등이 산업의 다양한 이해 관계자를 대상으로 합니다.
• 이해관계자는 세계의 혈장 유도체 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map (COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 세계에서 유전성 질환이나 희귀질환의 부담이 증가
  • 치료비가 높고, 부작용도 큼
  • 혈장 채취 센터 증가
• 영향 분석
• 규제 시나리오
• 제품 출시/승인
• PEST 분석
• Porter's Five Forces 분석
• 합병과 인수 시나리오

제4장 세계의 혈장 유도체 시장 - 코로나 바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측과 수요측의 분석
• 경제에 미치는 영향

제5장 세계의 혈장 유도체 시장 : 유형별, 2020-2032년

• 소개
• 알부민
• 제VIII인자
• 제IX인자
• 면역글로불린
• 고면역글로불린
• 기타

제6장 세계의 혈장 유도체 시장 : 용도별, 2020-2032년

• 소개
• 혈우병
• 저감마글로불린혈증
• 면역 결핍 질환
• 폰 빌레브란트 병(VWD)
• 기타

제7장 세계의 혈장 유도체 시장 : 지역별, 2020-2032년

• 소개
• 북미
• 라틴아메리카
• 유럽
• 아시아태평양
• 중동
• 아프리카

제8장 경쟁 구도

• Shire Plc.
• CSL Limited
• Octapharma AG
• LFB SA
• BIoTest AG
• Grifols, SA
• SK Plasma Co., Ltd.
• Baxter International Inc.
• Green Cross Corporation
• Fusion Health Care Pvt. Ltd.

제9장 섹션

• 조사 방법
• 출판사에 대해

영문목차

Blood Plasma Derivatives Market is estimated to be valued at USD 52.96 Bn in 2025 and is expected to reach USD 98.69 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.3% from 2025 to 2032.

Plasma is a liquid portion of blood. About 55% of the blood is plasma, and remaining 45% are red blood cells, white blood cells, and platelets that are suspended in the plasma. Products made from human plasma using plasma fractionation techniques are known as plasma derivatives. These are used in the treatment of various life threatening diseases.

Market Dynamics:

Rise in burden of genetic diseases, increasing geriatric population, high demand for blood plasma derivatives, growing use of immunoglobulins in various therapeutic areas, and increasing number of plasma collection centres are major factors expected to augment the growth of the global blood plasma derivatives market during the forecast period.

For instance, in March 2022, Sanofi SA and IGM Biosciences, Inc. collaborated to create, develop, manufacture, and commercialize immunoglobulin (IgM) antibody agonists against three oncology and immunology/inflammation targets. Engineered antibodies represent a new class of potential therapeutics that combine the multi-valency of antibodies possessing 10 binding sites compared to conventional IgG antibodies having only 2 target binding sites.

Key features of the study:

• This report provides in-depth analysis of the global blood plasma derivatives market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global blood plasma derivatives market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Shire Plc., CSL Limited, Octapharma AG, LFB S.A., Biotest AG, Grifols, S.A., SK Plasma Co., Ltd., Baxter International Inc., Green Cross Corporation, and Fusion Health Care Pvt. Ltd., among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global blood plasma derivatives market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global blood plasma derivatives market.

Detailed Segmentation:

• Global Blood Plasma Derivatives Market, By Type:
  • Albumin
  • Factor VIII
  • Factor IX
  • Immunoglobulin
  • Hyperimmune Globulin
  • Other
• Global Blood Plasma Derivatives Market, By Application:
  • Hemophilia
  • Hypogammaglobulinemia
  • Immunodeficiency Diseases
  • Von Willebrand' disease (VWD)
  • Other Application
• Global Blood Plasma Derivatives Market, By Geography:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles:
  • Shire Plc.
  • CSL Limited
  • Octapharma AG
  • LFB S.A.
  • Biotest AG
  • Grifols, S.A.
  • SK Plasma Co., Ltd.
  • Baxter International Inc.,
  • Green Cross Corporation
  • Fusion Health Care Pvt. Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Application
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rise in burden of genetic/rare diseases worldwide
  • High cost of treatment/therapy and side effects
  • Increasing number of plasma collection centres
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Blood Plasma Derivatives Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Blood Plasma Derivatives Market, By Type, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Albumin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Factor VIII
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Factor IX
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Immunoglobulin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Hyperimmune Globulin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Blood Plasma Derivatives Market, By Application, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hemophilia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Hypogammaglobulinemia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Immunodeficiency Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Von Willebrand Disease (VWD)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Other Application
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Blood Plasma Derivatives Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)

8. Competitive Landscape

• Shire Plc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• CSL Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Octapharma AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• LFB S.A.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Biotest AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Grifols, S.A.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• SK Plasma Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Baxter International Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Green Cross Corporation
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Fusion Health Care Pvt. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

9. Section

• Research Methodology
• About us